Trial Profile
Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis; Food hypersensitivity; Hypersensitivity; Peanut hypersensitivity
- Focus Therapeutic Use
- 27 Jul 2022 Status changed from recruiting to discontinued.
- 10 Jul 2020 New trial record